Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 31:3:30.
doi: 10.21037/tbcr-22-48. eCollection 2022.

Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)

Jianbin Li  1 , Xiaojia Wang  2 , Shusen Wang  3 , Shu Wang  4 , Tao Wang  1 , Yueping Liu  5 , Cuizhi Geng  5 , Feng Jin  6 , Yongmei Yin  7 , Qingyuan Zhang  8 , Erwei Song  9 , Jiong Wu  10 , Zefei Jiang  1 ; Chinese Society of Clinical Oncology Breast cancer committee; Chinese Anti-Cancer Association; Committee of Breast Cancer Society
Affiliations
Review

Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)

Jianbin Li et al. Transl Breast Cancer Res. .

Abstract

Human epidermal growth factor receptor 2 (HER2) is an important driver gene and prognostic indicator of breast cancer and also a key predictor of HER2-targeted therapies. The emerging anti-HER2 drugs have greatly changed the diagnosis and treatment modalities of breast cancer and dramatically improved the prognosis of HER2-positive breast cancer patients. To optimize the treatment of HER2 breast cancer an update of expert consensus on HER2 positive breast cancer was made to adjust the different recommendation levels from early stage to metastatic stage. Meanwhile, antibody-drug conjugate (ADC) like trastuzumab deruxtecan (T-Dxd) has been shown to have great efficacy in HER2-positive and HER2 low expression breast cancer patients. Clinically, on the basis of the original definition for HER2-negative breast cancer, patients with HER2 immunohistochemistry (IHC) 1+ or IHC 2+ and in-situ hybridization (ISH)-negative are defined as low HER2 expression (HER2-low). As both the low expression and the positive expression of the HER2 protein is clinically significant for disease treatment and prognosis, we added a new chapter of HER2 low to recommend a proper regimen for this kind of patients. In this consensus, we also talk about the importance of clinical research, real world evidence, biosimilars and so on. In addition, the whole-course management of HER2 breast cancer is even more critical during pandemic of coronavirus disease 2019 (COVID-19). An approach that gives preference to "low-toxicity regimens and oral preparations" are also recommended.

Keywords: Human epidermal growth factor receptor 2 (HER2); breast cancer; consensus; low expression.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.com/article/view/10.21037/tbcr-22-48/coif). XW serves as an unpaid editorial member of Translational Breast Cancer Research from December 2020 to November 2022. SSW, CG, FJ, YY, QZ, ES and JW serve as the unpaid editorial members of Translational Breast Cancer Research from March 2022 to April 2024. SW and YL serve as the unpaid editorial members of Translational Breast Cancer Research from May 2021 to April 2023. JL serves as an unpaid Managing Editor of Translational Breast Cancer Research from November 2019 to October 2024. ZJ serves as the Editor-in-Chief of Translational Breast Cancer Research. The other authors have no conflicts of interest to declare.

References

    1. CSCO BC , CACA-Breast cancner. Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer(2021 version). Zhonghua Yixue Zazhi 2021;101:1226-31.
    1. Jiang Z, Li J, Chen J, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022. Transl Breast Cancer Res 2022;3:13. 10.21037/tbcr-22-21 - DOI - PMC - PubMed
    1. Breast Cancer Expert Panel of HER2 testing. Guidelines for Her2 testing of breast cancer (2019). Zhonghua Binglixue Zazhi 2019;48:169-75.
    1. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791-800. 10.1016/S1470-2045(16)00163-7 - DOI - PubMed
    1. Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:e193692. 10.1001/jamaoncol.2019.3692 - DOI - PMC - PubMed